Benitec Biopharma (NASDAQ:BNTC) PT Raised to $16.00 at JMP Securities

Benitec Biopharma (NASDAQ:BNTC) had its target price increased by JMP Securities from $10.00 to $16.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 133.24% from the stock’s current price.

Benitec Biopharma Stock Up 2.1 %

BNTC stock opened at $6.86 on Monday. The firm’s fifty day simple moving average is $4.99 and its 200-day simple moving average is $3.85. The company has a quick ratio of 3.62, a current ratio of 3.62 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 12 month low of $1.86 and a 12 month high of $9.01.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported ($2.64) EPS for the quarter.

Hedge Funds Weigh In On Benitec Biopharma

A hedge fund recently bought a new stake in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. bought a new stake in Benitec Biopharma Inc. (NASDAQ:BNTC) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned 7.42% of Benitec Biopharma at the end of the most recent reporting period. Institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.